Increasing the rate of excisional lymph node biopsies at easily accessible sites when ruling out lymphoma
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Problem Definition

Intervention

We
have
reviewed
all
lymph
node
biopsies
Excisional biopsy is the gold standard for
performed
at
easily
accessible
sites
at
the
Center
diagnosing lymphoma. In our previous analysis of
City
campus
from
January
to
December
2020,
in
457 biopsy samples performed at TJUH from
order
to
identify
change
concepts
for
a
PDSA
cycle
2016-2019 (QR code), we confirmed that
in
the
context
of
the
most
current
practices.
excisional biopsy of lymph nodes in patients with
suspected lymphoma should remain
the standard of care. However, core
needle biopsies (CNBs) have been
ordered with increasing frequency
à75 total lymph nodes, with an excisional biopsy
(19%-27.7%) even for lymph nodes
rate of 65%
that can be surgically excised with ease- namely,
àLymphoma was primary differential in 46% of
axilla (34.7%), inguinal (14.4%), supraclavicular
CNBs performed
(11.9%), and cervical (8.5%)- leading to repeat
àProcess
measures
analyzed:
biopsies (diagnostic accuracy of excisional versus
àDate
of
specimen
collection
CNB is 96.8% versus 56.8%, respectively).
àPatient location (outpatient versus
CNB in patients with suspected lymphoma
inpatient)
àMembers of care team involved and
discussion of CNB versus excisional biopsy
Inadequate tissue for accurate
pathologic diagnosis
CNBs at easily accessible sites,
January-December 2020
Delay in high quality patient care
8%
Axilla
15%
Inguinal
38%
Supraclavicular
The aim of this study is to increase the rate of
8%
Cervical
excisional lymph node biopsies from 78% to 95%
in patients presenting to the Center City campus
Other
with lymphadenopathy at easily accessible sites
31%
by September 2021.

Measurements/Results

Aims For Improvement

Next Steps and
Lessons Learned
Next steps include identification of key
drivers to meet ultimate aim for
improvement of increasing the rate of
excisional lymph node biopsies to 95%
of cases of suspected lymphoma by
September 2021.
Data analysis thus far has revealed
several opportunities for further
intervention:
àConsistent involvement of both
medical oncology and surgery when
1) lymphoma is high on the
differential in a patient presenting
with lymphadenopathy and 2) when
there is a discussion as to whether a
CNB or excisional biopsy should be
performed.
àDevelopment or improvement upon
algorithms for patients presenting
with lymphadenopathy.
We hope to conduct an
interprofessional PDSA cycle based on
an actionable intervention identified
through our analyses and will repeat
cycles pending our results.

